Search Within

Solid Tumor Oncology Division

  1. "Oncology Research and Treatment"
Formats
  1. Meeting Abstract (131)
  2. Journal Article (1)
Groups
  1. Department of Medicine (132)
  2. Gastrointestinal Oncology Service (46)
  3. Thoracic Oncology (44)
  4. Genitourinary Oncology Service (27)
  5. Center for Pancreatic Cancer Research (9)
  6. GSK Faculty (8)

More Groups

People
  1. Alexander Drilon (23)
  2. Robert Motzer (20)
  3. Ghassan Abou-Alfa (18)
  4. Yelena Janjigian (11)
  5. Matthew Hellmann (9)
  6. Eileen O'Reilly (8)

More People

Years
  1. 2024 (10)
  2. 2023 (14)
  3. 2022 (24)
  4. 2021 (16)
  5. 2020 (29)
  6. 2019 (11)

More Years

Publications
  1. Oncology Research and Treatment (132)
Publishers
  1. S. Karger AG (132)

Results (132)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
    Meeting Abstract

    Möhler, M.; Janjigian, Y.; Al-Batran, S. E.; Wainberg, Z.; Van Cutsem, E.; Molena, D.; Muro, K.; Hyung, W. J.; Wyrwicz, L.; Oh, D. Y.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Inavolisib or placebo in combination with palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer: Phase III INAVO120 primary analysis
    Meeting Abstract

    Kümmel, S.; Jhaveri, K.; Im, S. A.; Saura, C.; Juric, D.; Loibl, S.; Kalinsky, K.; Schmid, P.; Loi, S.; Thanopoulou, E.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer
    Meeting Abstract

    Hadoux, J.; Elisei, R.; Brose, M.; Hoff, A.; Robinson, B.; Gao, M.; Jarzab, B.; Isaev, P.; Kopeckova, K.; Wadsley, J.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Randomized phase 3 study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC
    Meeting Abstract

    Loong, H.; Goto, K.; Solomon, B.; Park, K.; Pérol, M.; Arriola, E.; Novello, S.; Cheng, Y.; Ardizzoni, A.; Mak, M.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
    Meeting Abstract

    Möhler, M.; Janjigian, Y. Y.; Shitara, K.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Bragagnoli, A.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Sangro, B.; Chan, S. L.; Kelley, K.; Lau, G.; Kudo, M.; Sukeepaisarnjaroen, W.; De Toni, E.; Furuse, J.; Kang, Y. K.; Galle, P. R.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
    Meeting Abstract

    Vogel, A.; Chan, S. L.; Furuse, J.; Tak, W. Y.; Masi, G.; Varela, M.; Kim, J. H.; Tanasanvimon, S.; Reig, M.; Dayyani, F.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Impact of viral aetiology in the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Chan, S. L.; Kudo, M.; Sangro, B.; Kelley, K.; Furuse, J.; Park, J. W.; Sunpaweravong, P.; Fasolo, A.; Yau, T.; Kawaoka, T.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+ metastatic colorectal cancer (MOUNTAINEER-03, trial in progress)
    Meeting Abstract

    Heinemann, V.; André, T.; Bekaii-Saab, T.; Cercek, A.; Nakamura, Y.; Raghav, K.; Siena, S.; Strickler, J.; Van Cutsem, E.; Adelberg, D.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save
  • Phase II, single-arm, open-label study of dostarlimab monotherapy in previously untreated patients with stage II/III dMMR/MSI-H locally advanced rectal cancer: Trial in progress
    Meeting Abstract

    Cercek, A.; Bachet, J. B.; Capdevilla, J.; Starling, N.; Chen, E.; Di Bartolomeo, M.; Yoshino, T.; Vlahovic, G.; Zografos, E.; O'donnell, S.; more...
    Oncology Research and Treatment (2024)

    Fulltext@MSK | Save